The Rotavirus Vaccine is a critical tool in the prevention of rotavirus infections, which are a leading cause of severe diarrhea and dehydration in infants and young children worldwide. Rotavirus is highly contagious and spreads through the fecal-oral route, making it particularly challenging to control. The vaccine helps to protect against rotavirus by stimulating the immune system to produce antibodies that target the virus. There are two main types of rotavirus vaccines available: the oral live attenuated vaccine and the oral inactivated vaccine. Both types of vaccines are administered orally and have been shown to be safe and effective in preventing rotavirus infections.
The live attenuated rotavirus vaccine is administered in two or three doses, depending on the vaccine formulation, typically starting at around 6 to 8 weeks of age. This vaccine contains weakened forms of the rotavirus strains that are most commonly associated with severe illness. When administered, the vaccine stimulates the immune system to produce a protective response against these strains, reducing the risk of rotavirus infection and its complications. The inactivated rotavirus vaccine is administered in two doses, typically starting at around 2 to 6 months of age. This vaccine contains killed rotavirus strains and is administered orally in a liquid form. Similar to the live attenuated vaccine, the inactivated vaccine stimulates the immune system to produce antibodies against rotavirus, providing protection against infection.
Both types of rotavirus vaccines have been shown to be highly effective in preventing severe rotavirus gastroenteritis and reducing hospitalizations and deaths associated with rotavirus infection. Vaccination with the rotavirus vaccine has led to significant declines in the incidence of rotavirus-related hospitalizations and deaths in countries where it has been introduced into routine immunization programs. The rotavirus vaccine is typically recommended as part of routine childhood immunization schedules in many countries around the world. It is considered safe and well-tolerated, with the most common side effects being mild and temporary, such as fever or mild diarrhea.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States